A 640 Index Index abiraterone acetate, 5 7 Abraxane. See albuminbound paclitaxel ABVD regimen, 57, 540 ABV regimen, 519 520 AC docetaxel regimen, 476, 478 acetaminophen busulfan and, 71 AC regimen, 475, 481, 506 actinic keratoses 5-fluorouracil 05 Actinomycin-D. See dactinomycin-d ACT regimen, 475 AC T regimen, 476, 477 478 AC T 1 trastuzumab regimen, 478 479 acute leukemias carboplatin and, 87 primary induction acute lymphoblastic leukemia (ALL) asparaginase and, 34 clofarabine, 112 daunorubicin and, 139 idarubicin 29 mercaptopurine 83 methotrexate 86 primary induction T-cell, 303 thioguanine and, 393 acute lymphocytic leukemia 521 524 cytarabine and, 122 imatinib 37, 238 acute myelogenous leukemia (AML) 525 527 cytarabine and, 122 daunorubicin and, 139 etoposide phosphate and, 190 hydroxyurea 22 idarubicin 29 mitoxantrone 99 thioguanine and, 393 acute promyelocytic leukemia (APL) arsenic trioxide, 30, 31 tretinoin and, 415 Adcetris. See brentuximab adjuvant treatment to local treatment modalities, 2 3 ADOC regimen, 581 ado-trastuzumab emtansine, 8 10, 487 AD regimen, 576 adrenal steroid inhibitor aminoglutethimide, 23 25 adrenocortical cancer mitotane 96 adrenolytic agent mitotane, 295 297 Adriamycin. See doxorubicin Afinitor. See everolimus AG-13736. See axitinib AIDA regimen, 525 a-interferon. See interferon-a AI regimen, 577 albumin-bound paclitaxel, 11 13 alcohol lomustine 71 nilutamide and, 309 procarbazine and, 353 thalidomide and, 389 aldesleukin, 14 16 alemtuzumab, 17 19, 529 450, 457 Alimta. See pemetrexed Alkeran. See melphalan alkylating agents bendamustine, 44 46 busulfan, 70 72 carmustine, 93 95 chlorambucil, 100 102, 117 120 dacarbazine, 129 131 ifosfamide, 232 235 lomustine, 270 272 mechlorethamine, 273 275 melphalan, 279 281 streptozocin, 371 373 thiotepa, 395 397 ALL. See acute lymphoblastic leukemia (ALL) allopurinol ifosfamide 34 mercaptopurine 83 All- trans -retinoic acid. See tretinoin Aloxi. See palonosetron altretamine, 20 22 450, 457 aluminum hydroxide, capecitabine and, 83 Amethopterin. See methotrexate amifostine cisplatin and, 105 450 2-amino-9-b-D-arabinofu- ranosyl-6-methoxy- 9H-purine. See nelarabine aminoglutethimide, 23 25 450, 457 megestrol acetate 77 aminoglycosides cisplatin and, 105 amiodarone AML. See acute myelogenous leukemia (AML)
AMN107. See nilotinib amphotericin B carmustine and, 94 cisplatin and, 105 amputees (adult), body surface area of, 450 amsacrine dialysis guidelines, 462 451 anal cancer 467 468 5-fluorouracil 05 neoadjuvant anaplastic astrocytomas adjuvant and, 3 temozolomide and, 383 anaplastic large cell lymphoma brentuximab and, 68 anastrozole, 26 28, 480, 486 adjuvant treatment to local treatment modalities, 3 antacids vismodegib and, 439 anthracyclines trastuzumab and, 412 antiandrogen bicalutamide, 54 55 enzalutamide, 167 169 flutamide, 208 209 nilutamide, 308 310 anti-angiogenic agent lenalidomide, 260 263 pomalidomide, 341 344 thalidomide, 388 391 antibody-drug conjugate ado-trastuzumab emtansine, 8 10 anticoagulants antidiabetic agents procarbazine and, 353 anti-egfr antibody cetuximab, 96 99 panitumumab, 327 329 antiemetic agents aprepitant, 602 603, 633 634 dexamethasone, 604 605, 632, 633 diphenhydramine, 606 607 dolasetron, 608 610, 632, 633, 635 dronabinol, 611 612, 635 granisetron, 106, 613 615 lorazepam, 616 618 metoclopramide, 619 621, 632, 634, 635 nabilone, 622 623, 635 ondansetron, 106, 624 626, 632, 633, 634 635 overview, 601 palonosetron, 627 629, 633, 634 prochlorperazine, 630 631, 632, 635 antiestrogen tamoxifen, 378 381 toremifene, 401 403 Anti-HER-2-antibody. See pertuzumab; trastuzumab antihistamines diphenhydramine, 606 607 procarbazine and, 353 antimetabolite azacitidine, 41 43 capecitabine, 80 85 cladribine, 108 110 clofarabine, 111 113 cytarabine, 121 125 decitabine, 145 147 floxuridine, 197 200 fludarabine, 201 203 5-fluorouracil, 204 207 gemcitabine, 215 218 hydroxyurea, 221 223 mercaptopurine, 282 284 methotrexate, 285 290 nelarabine, 302 304 pemetrexed, 334 337 pralatrexate, 349 351 thioguanine, 392 394 antimicrotubule agent albumin-bound paclitaxel, 11 13 cabazitaxel, 73 76 docetaxel, 153 157 eribulin, 174 176 estramustine, 181 183 ixabepilone, 254 256 paclitaxel, 322 326 vinblastine, 426 429 vincristine, 430 433 vinorelbine, 434 437 antineoplastic agent decitabine, 145 147 antithymocyte globulin (ATG) 1 cyclosporine regimen, 563 antitumor antibiotic bleomycin, 56 59 dactinomycin-d, 132 134 daunorubicin, 138 141 daunorubicin liposome, 142 144 doxorubicin, 158 162 doxorubicin liposome, 163 166 epirubicin, 170 173 mitomycin-c, 291 294 mitoxantrone, 298 301 antitumor antibiotics idarubicin, 228 231 anti-vegf antibody bevacizumab, 47 50 ziv-aflibercept, 444 446 Anzemet. See dolasetron AP24534. See ponatinib APC8015. See sipuleucel-t APL. See acute promyelocytic leukemia (APL) AP regimen, 506 aprepitant, 602 603, 633 634 Ara-C. See cytarabine area under the curve (AUC), 449 Arimidex. See anastrozole Aromasin. See exemestane aromatase inhibitor letrozole, 264 266 Arranon. See nelarabine Index 641
642 Index arsenic trioxide (As 2 O 3 ), 29 32, 527 Arzerra. See ofatumumab asparaginase, 33 36 cytarabine and, 124 methotrexate 88 vincristine and, 432 aspirin methotrexate 87 pemetrexed and, 336 pralatrexate and, 350 astemizole astrocytomas, 94 anaplastic, 3, 383 atazanavir A T C, 478 Ativan. See lorazepam ATRA. See tretinoin ATRA regimen, 527 AT regimen, 481 AUC. See area under the curve (AUC) Avastin. See bevacizumab axitinib, 37 40 azacitidine, 41 43, 527, 562 451 5-Aza-2 -deoxycytidine. See decitabine azidothymidine (AZT) hydroxyurea 22 azithromycin vismodegib and, 439 B barbiturates mitotane 96 thalidomide and, 389 basal cell carcinoma regimens, 469 5-fluorouracil 05 vismodegib and, 439 BAY 43-9006. See sorafenib BAY 73-4506. See regorafenib B-cell chronic lymphocytic leukemia (B-CLL) alemtuzumab and, 17 BCNU. See carmustine BCNU regimen, 473 474 BEACOPP regimen, 542 Benadryl. See diphenhydramine bendamustine, 44 46, 530, 552 benzodiazepine lorazepam, 616 618 BEP regimen, 568, 579 bepridil bevacizumab, 47 50, 475, 519 bexarotene, 51 53 Bexxar. See tositumomab bicalutamide, 54 55, 220 BIC regimen, 492 biliary tract cancer, regimens, 469 470 biologic response modifier agent ado-trastuzumab emtansine, 8 10 aldesleukin, 14 16 alemtuzumab, 17 19 bevacizumab, 47 50 brentuximab, 67 69 cetuximab, 96 99 denileukin difitox, 150 152 ibritumomab, 224 227 interferon-a, 241 244 ipilimumab, 245 248 lenalidomide, 260 263 ofatumumab, 311 314 panitumumab, 327 329 pertuzumab, 338 340 pomalidomide, 341 344 rituximab, 355 358 sipuleucel-t, 366 367 thalidomide, 388 391 tositumomab, 404 407 trastuzumab, 411 413 ziv-aflibercept, 444 446 BIP regimen, 491 Bischloroethylnitrosourea. See carmustine bladder cancer carboplatin and, 87 470 473 cisplatin and, 104 docetaxel and, 154 gemcitabine 17 ifosfamide 33 methotrexate 86 mitomycin-c and, 292 neoadjuvant paclitaxel and, 323 thiotepa and, 396 Blenoxane. See bleomycin bleomycin, 56 59 brentuximab and, 68 cisplatin and, 105 BMP regimen, 561 BMPT regimen, 561 BMS-247550. See ixabepilone BMS-354825. See dasatinib body surface area (BSA) of amputees (adult), 450 dosage determination from, 449 450 bone sarcoma
bortezomib, 60 63, 553, 562 doxorubicin liposome and, 164 Bosulif. See bosutinib bosutinib, 64 66, 531 451 brain stem glioma, 94 brain tumor carmustine and, 94 473 475 lomustine 71 procarbazine and, 353 breast cancer adjuvant treatment to local treatment modalities, 3 ado-trastuzumab emtansine for, 9 albumin-bound paclitaxel for, 12 aminoglutethimide 3 anastrozole 7 capecitabine and, 82 475 488 docetaxel and, 154, 155 epirubicin and, 171 etoposide and, 185 exemestane and, 196 5-fluorouracil 05 fulvestrant 11 gemcitabine 16 ixabepilone 55 lapatinib 58 letrozole 65 megestrol acetate 77 melphalan 80 methotrexate 86 mitomycin-c 92 mitoxantrone 99 neoadjuvant optimal duration of drug administration, 4 paclitaxel and, 323 tamoxifen and, 379 thiotepa and, 396 toremifene and, 402 trastuzumab and, 412 vinorelbine and, 435 brentuximab, 67 69, 553 bleomycin and, 58 bretylium BSA. See body surface area (BSA) bupropion Burkitt s lymphoma 549 551 primary induction buserelin busulfan, 70 72, 531 Busulfex. See busulfan BV regimen, 519 C cabazitaxel, 73 76 cabozantinib, 77 79 CAE regimen, 539 540 CAF regimen, 477, 481 calcium channel blockers Calvert formula, for carboplatin dose, 87 Campath. See alemtuzumab Camptosar. See irinotecan cancer of unknown primary, 488 489 cannabinoid dronabinol, 611 612 nabilone, 622 623 capecitabine, 80 85, 487, 496, 504, 519, 571 CAP regimen, 472, 506, 557, 580 Caprelsa. See vandetanib carbamazepine cabozantinib and, 78 dasatinib and, 136 erlotinib and, 178 everolimus and, 192 exemestane and, 196 gefitinib 13 imatinib 38 ironotecan 51 ixabepilone 55 lapatinib 58 letrozole 65 nilotinib and, 306 temsirolimus and, 386 toremifene and, 402 carboplatin, 86 89 albumin-bound paclitaxel for non small cell lung cancer, 12 area under the curve, 449 paclitaxel and, 324 carcinoid tumors 489 490 streptozocin and, 372 carcinomatous meningitis methotrexate 86 carfilzomib, 90 92, 562 Index 643
644 Index carmustine, 93 95 451, 457 Casodex. See bicalutamide CAV alternating with IE regimen, 578 CAV regimen, 539 CBDCA. See carboplatin CC-5013. See lenalidomide CCI-779. See temsirolimus CCNU. See lomustine CC regimen, 564 2-CdA. See cladribine CDDP. See cisplatin CEF regimen, 481 CEL. See chronic eosinophilic leukemia (CEL) cephalosporins methotrexate 87 pralatrexate and, 350 Cerubidine. See daunorubicin cervical cancer 491 493 ifosfamide 33 mitomycin-c 92 topotecan and, 399 Cesamet. See nabilone cetuximab, 96 99, 504 505, 518 CF regimen, 511, 527 adjuvant treatment to local treatment modalities, 2 3 clinical efficacy, obstacles to, 1 combination, 3 4 guidelines (See guidelines, ) neoadjuvant, 2 overview, 1 primary induction, 2 principles of, 1 4 salvage, 468 drugs ado-trastuzumab emtansine, 8 10 albumin-bound paclitaxel, 11 13 altretamine, 20 22 arsenic trioxide, 29 32 asparaginase, 33 36 axitinib, 37 40 azacitidine, 41 43 bendamustine, 44 46 bleomycin, 56 59 bortezomib, 60 63 bosutinib, 64 66 busulfan, 70 72 cabazitaxel, 73 76 cabozantinib, 77 79 capecitabine, 80 85 carboplatin, 86 89 carfilzomib, 90 92 carmustine, 93 95 chlorambucil, 100 102 cisplatin, 103 107 cladribine, 108 110 clofarabine, 111 113 crizotinib, 114 116, 117 120 cytarabine and, 121 125 dabrafenib, 126 128 dacarbazine, 129 131 dactinomycin-d, 132 134 dasatinib, 135 137 daunorubicin, 138 141 daunorubicin liposome, 142 144 docetaxel, 153 157 doxorubicin, 158 162 doxorubicin liposome, 163 166 emetogenic potential of, 636 639 epirubicin, 170 173 eribulin, 174 176 erlotinib, 177 180 estramustine, 181 183 etoposide, 184 187 etoposide phosphate, 188 190 everolimus, 191 194 floxuridine, 197 200 fludarabine, 201 203 5-fluorouracil, 204 207 gefitinib, 212 214 gemcitabine, 215 218 hydroxyurea, 221 223 idarubicin, 228 231 ifosfamide, 232 235 imatinib, 236 240 ironotecan, 249 253 ixabepilone, 254 256 lapatinib, 257 259 lomustine, 270 272 mechlorethamine, 273 275 melphalan, 279 281 mercaptopurine, 282 284 methotrexate, 285 290 mitomycin-c, 291 294 mitotane, 295 297 mitoxantrone, 298 301 nelarabine, 302 304 nilotinib, 305 307 omacetaxine mepesuccinate, 315 317 oxaliplatin, 318 321 paclitaxel, 322 326 pazopanib, 330 333 pemetrexed, 334 337 ponatinib, 345 348 pralatrexate, 349 351 procarbazine, 352 354 regorafenib, 355 358 romidepsin, 363 365 sorafenib, 368 370 streptozocin, 371 373 sunitinib, 374 377 temozolomide, 382 384 temsirolimus, 385 387 thioguanine, 392 394 thiotepa, 395 397 topotecan, 398 400 trametinib, 408 410 vandetanib, 418 421 vemurafenib, 422 425 vinblastine, 426 429 vincristine, 430 433 vinorelbine, 434 437 vismodegib, 438 440 vorinostat, 441 443 466 582. See also specific drugs acute lymphocytic leukemia, 521 524 acute myelogenous leukemia, 525 527 anal cancer, 467 468 basal cell carcinoma, 469 biliary tract cancer, 469 470
bladder cancer, 470 473 brain tumor, 473 475 breast cancer, 475 488 Burkitt s lymphoma, 549 551 cancer of unknown primary, 488 489 carcinoid tumors, 489 490 cervical cancer, 491 493 chronic lymphocytic leukemia, 527 530 chronic myelogenous leukemia, 530 531 colorectal cancer, 493 505 endometrial cancer, 505 507 esophageal cancer, 507 510 gastric cancer, 510 513 gastrointestinal stromal tumor, 513 514 hairy cell leukemia, 531 head and neck cancer, 514 518 hepatocellular cancer, 518 519 Hodgkin s lymphoma, 540 543 Kaposi s sarcoma, 519 520 lymphoma, 540 554 malignant melanoma, 555 557 malignant mesothelioma, 557 558 multiple myeloma, 558 562 myelodysplastic syndrome, 562 563 non-hodgkin s lymphoma, 543 553 non-small cell lung cancer, 532 538 osteogenic sarcoma, 563 564 ovarian cancer, 564 568 pancreatic cancer, 568 571 primary CNS lymphoma, 553 554 prostate cancer, 571 575 renal cell cancer, 575 576 small cell lung cancer, 538 540 soft tissue sarcoma, 576 578 testicular cancer, 578 580 thymoma, 580 581 thyroid cancer, 581 582 chlorambucil, 100 102, 529 2-Chlorodeoxyadenosine. See cladribine chloroquine chlorpromazine thalidomide and, 389 CHOP regimen, 544, 545 CHOP 1 rituximab regimen, 546 choriocarcinoma primary induction chronic eosinophilic leukemia (CEL) imatinib 38 chronic leukemias chronic lymphocytic leukemia (CLL) bendamustine and, 45 527 530 chlorambucil and, 101 cladribine and, 109 fludarabine 02 ofatumumab and, 312 chronic myelogenous leukemia (CML) busulfan and, 71 regimens, 530 531 cytarabine and, 123 dasatinib and, 136 hydroxyurea 22 idarubicin 29 imatinib 37 interferon-a 42 nilotinib and, 306 omacetaxine mepesuccinate and, 316 thioguanine and, 393 chronic myelomonocytic leukemia azacitidine and, 42 cimetidine carmustine and, 94 epirubicin and, 171 ifosfamide 34 lomustine 71 melphalan 80 tretinoin and, 415 ciprofloxacin Cis-diamminedichloroplatinum,. See cisplatin cisplatin, 103 107, 519 bleomycin and, 57 cytarabine and, 123 fludarabine 02 gemcitabine 17 granisetron and, 614 ifosfamide 34 paclitaxel and, 324 vincristine and, 432 vinorelbine and, 435 cladribine, 108 110, 526, 529, 552 451, 458 clarithromycin cabozantinib and, 78 dasatinib and, 136 erlotinib and, 179 everolimus and, 193 exemestane and, 196 gefitinib 13 Index 645
646 Index clarithromycin Cont. imatinib 38 ironotecan 51 ixabepilone 55 lapatinib 58 letrozole 65 nilotinib and, 306 temsirolimus and, 386 vismodegib and, 439 CLL. See chronic lymphocytic leukemia (CLL) clofarabine, 111 113, 524, 527 Clolar. See clofarabine clopidogrel (plavix) letrozole 65 CMF regimen, 482 CML. See chronic myelogenous leukemia (CML) CMV regimen, 471 CNOP regimen, 544, 546 CNS lymphoma, primary 553 554 methotrexate 86 CODOX-M regimen, 550 colon cancer capecitabine and, 82 oxaliplatin and, 319 colorectal cancer adjuvant treatment to local treatment modalities, 3 bevacizumab and, 48 capecitabine and, 82 493 505 floxuridine and, 198 5-fluorouracil 05 ironotecan and, 250, 251 optimal duration of drug administration, 4 oxaliplatin and, 319 panitumumab and, 328 ziv-aflibercept and, 445 combination, 3 4 Cometriq. See cabozantinib Compazine. See prochlorperazine Cosmegen. See dactinomycin-d coumadin mercaptopurine 83 CP regimen, 527, 564 CPT-11. See irinotecan creatinine clearance, determination of, 448 449 crizotinib, 114 116 Crockcroft-Gault formula, for creatinine clearance, 448 449 CTCL. See cutaneous T-cell lymphoma (CTCL) CT regimen, 565 CTX. See cutaneous T-cell lymphoma (CTCL) bexarotene and, 51, 52 denileukin difitox and, 150 fludarabine 02 interferon-a 42 mechlorethamine 74 procarbazine and, 353 vorinostat and, 442 CVP regimen, 527, 543, 117 120 and busulfan in stem cell transplant, 71 doxorubicin and, 160 epirubicin and, 171 fludarabine 02 mitotane 96 paclitaxel and, 324 rituximab and, 360 tamoxifen and, 379 cyclosporine docetaxel and, 155 melphalan 80 tretinoin and, 415 Cytadren. See aminoglutethimide cytarabine, 121 125, 526 fludarabine 02 cytokines aldesleukin, 14 16 cytarabine and, 124 Cytosine arabinoside. See cytarabine Cytoxan. See CYVADIC regimen, 577 D DAB389. See denileukin difitox dabrafenib, 126 128 452 dacarbazine, 129 131 Dacogen. See decitabine dactinomycin dactinomycin-d, 132 134 dasatinib, 135 137, 524, 530 458 Daunomycin. See daunorubicin daunorubicin, 138 141, 520 daunorubicin liposome, 142 144 DaunoXome. See daunorubicin liposome DCF regimen, 511
DCIS. See ductal carcinoma in situ (DCIS) Decadron. See dexamethasone decitabine, 145 147, 527, 562 degarelix, 148 149 degramont regimen, 496, 501 4-Demethoxydaunorubicin. See idarubicin denileukin difitox, 150 152 depsipeptide. See romidepsin dexamethasone, 561, 604 605, 632, 633 daunorubicin and, 139 everolimus and, 192 dexrazoxane daunorubicin and, 139 doxorubicin and, 160 dextromethorphan DHAP (salvage regimen), 548 DH FEC regimen, 479 Diaminocyclohexane platinum. See oxaliplatin DIC. See dacarbazine dideoxycytidine (ddc) hydroxyurea 22 dideoxyinosine (ddi) hydroxyurea 22 differentiating agents arsenic trioxide, 29 32 bexarotene, 51 53 tretinoin, 414 417 digoxin carmustine and, 94 cytarabine and, 123 vincristine and, 432 dilantin dasatinib and, 136 erlotinib and, 178 exemestane and, 196 gefitinib 13 imatinib 38 ironotecan 51 ixabepilone 55 lapatinib 58 letrozole 65 nilotinib and, 306 diltiazem everolimus and, 193 tretinoin and, 415 diphenhydramine, 606 607 disopyramide docetaxel, 153 157, 487, 493, 513, 517, 520 and abiraterone acetate for prostate cancer, 6 capecitabine and, 82 pertuzumab and, 339 docetaxel AC regimen, 478 dofetilide dolasetron, 608 610, 632, 633, 635 Douillard regimen, 497 Doxil. See doxorubicin liposome doxorubicin, 158 162, 487, 488, 507, 519, 520 452 paclitaxel and, 324 doxorubicin liposome, 163 166 dronabinol, 611 612, 635 droperidol DTIC 1 BCNU 1 cisplatin regimen, 555 DTIC-Dome. See dacarbazine ductal carcinoma in situ (DCIS) tamoxifen and, 379 duloxetine DVD regimen, 560 E ECF regimen, 509, 511 ECOG performance scale, 448 ECOG regimen, 569 EC regimen, 539 ECX regimen, 510, 512 Efudex. Se e 5-fluorouracil Ellence. See epirubicin Eloxatin. See oxaliplatin Elspar. See asparaginase embryonal rhabdomyosarcoma primary induction Emcyt. See estramustine Emend. See aprepitant endometrial cancer carboplatin and, 87 505 507 megestrol acetate 77 tamoxifen and, 379 ENL. See erythema nodosum leprosum (ENL) enzalutamide, 167 169 enzymes asparaginase, 33 36 EOF regimen, 510, 511 EORTC regimen, 467 EOX regimen, 510, 512 EP 1 docetaxel regimen, 536 ependymoma, 94 4 Epi-doxorubicin. See epirubicin epipodophyllotoxin etoposide, 184 187 etoposide phosphate, 188 190 Index 647
648 Index epirubicin, 170 173 EPOCH regimen, 546 EPOCH 1 rituximab regimen, 547 epothilone ixabepilone, 254 256 EP regimen, 488, 536, 538, 579 Erbitux. See cetuximab eribulin, 174 176, 488 Erivedge. See vismodegib erlotinib, 177 180 erythema nodosum leprosum (ENL) thalidomide and, 389 erythromycin bexarotene and, 52 cabozantinib and, 78 dasatinib and, 136 docetaxel and, 155 erlotinib and, 179 everolimus and, 193 exemestane and, 196 gefitinib 13 imatinib 38 ironotecan 51 ixabepilone 55 lapatinib 58 letrozole 65 nilotinib and, 306 temsirolimus and, 386 toremifene and, 402 tretinoin and, 415 vismodegib and, 439 ESHAP (salvage regimen), 548 esophageal cancer regimens, 507 510 cisplatin and, 104 5-fluorouracil 05 neoadjuvant paclitaxel and, 323 Estracyte. See estramustine estramustine, 181 183 estrogen receptor antagonist fulvestrant, 210 211 Etopophos. See etoposide phosphate etoposide, 184 187, 520 cisplatin and, 105 etoposide phosphate, 188 190 Eulexin. See flutamide EVAP regimen, 542 EVA regimen, 541 everolimus, 191 194, 490 Ewing s sarcoma dactinomycin-d, 133 ifosfamide 33 exemestane, 195 196, 486 F Fareston. See toremifene Faslodex. See fulvestrant FC regimen, 544 FCR regimen, 527, 544 FEC docetaxel regimen, 477 FEC regimen, 477 FEC-50 regimen, 483 FEC-75 regimen, 483 FEC-100 regimen, 483 Femara. See letrozole FFD French regimen, 508 filgrastim vincristine and, 432 Firmagon. See degarelix FLAG regimen, 526 FLO regimen, 513 FLOX regimen, 496 floxuridine, 197 200, 504 453, 458 fluconazole everolimus and, 193 ixabepilone 55 Fludara. See fludarabine fludarabine, 201 203, 529, 552 alemtuzumab, 17 cytarabine and, 123 453, 458 rituximab and, 360 2-Fluoro-ara-AMP. See fludarabine 5-fluorocytosine cytarabine and, 123 5-Fluoro-2 -deoxyuridine. See floxuridine 5-fluorouracil, 204 207, 505 colorectal cancer and irinotecan, 251 453, 458 epirubicin and, 171 hydroxyurea 22 methotrexate 87 pemetrexed and, 336 fluoxetine flutamide, 208 209, 220 453, 459 FND regimen, 544 FOLFIRI 1 bevacizumab regimen, 503 FOLFIRI 1 cetuximab regimen, 502 FOLFIRINOX regimen, 570 FOLFIRI 1 panitumumab regimen, 503 FOLFIRI regimen, 497 FOLFIRI 1 ziv-aflibercept regimen, 503 504
FOLFOX 4 1 bevacizumab regimen, 501 FOLFOX 1 cetuximab 4 regimen, 502 FOLFOX6 1 cetuximab regimen, 502 503 FOLFOXIRI regimen, 499 FOLFOX 4 1 panitumumab regimen, 503 FOLFOX regimen, 495, 4 498, 518 FOLFOX regimen, 498 6 FOLFOX 7 regimen, 498 folic acid supplements methotrexate 87 Folotyn. See pralatrexate FP regimen, 527 FP 1 trastuzumab regimen, 513 FR regimen, 527 5-FU. See 5-fluorouracil FUDR. See floxuridine fulvestrant, 210 211, 486 furosemide cisplatin and, 105 G gastric cancer adjuvant treatment to local treatment modalities, 3 510 513 docetaxel and, 154, 155 epirubicin and, 171 etoposide and, 185 5-fluorouracil 05 mitomycin-c 92 trastuzumab and, 412 gastroesophageal cancer oxaliplatin and, 319 trastuzumab and, 412 gastrointestinal (GI) adenocarcinoma floxuridine and, 198 gastrointestinal stromal tumor (GIST) adjuvant treatment to local treatment modalities, 3 513 514 imatinib 37, 238 optimal duration of drug administration, 4 GBM. See glioblastoma multiformae (GBM) GCB regimen, 534 GCP regimen, 489 gefitinib, 212 214 453, 459 GEM-CAP regimen, 569 gemcitabine, 215 218, 472, 487, 493, 570 571 453, 459 gemfibrozil bexarotene and, 52 GEMOX regimen, 518 gemtuzumab, 527 Gemzar. See gemcitabine gentamicin cytarabine and, 123 German AIO regimen, 493 494 German schedule, low dose regimen, 500 germ cell cancer bleomycin and, 57 carboplatin and, 87 dactinomycin-d, 133 etoposide and, 185 etoposide phosphate and, 189 ifosfamide 33 ovarian, 568 primary induction gestational trophoblastic disease dactinomycin-d, 133 methotrexate 86 GITSG regimen, 568 Gleevec. See imatinib Gliadel, 94. See also carmustine glioblastoma, bevacizumab and, 48 glioblastoma multiformae (GBM) carmustine and, 94 temozolomide and, 383 glucocorticoid steroid dexamethasone, 604 605 GnRH antagonist degarelix, 148 149 goserelin, 219 220 453, 459 granisetron, 613 615, 632 633 cisplatin and, 106 grapefruit juice grepafloxacin GTX regimen, 569 guidelines, area under the curve, 449 body surface area in adult amputees, 450 creatinine clearance, 448 449 dialysis of drugs, 462 464 drug dose determination of, 449 450 hepatic function and, 450 456 renal function and, 457 461 patient factors, 447 performance scales, 448 GVD regimen, 543 GW572016. See lapatinib H hairy cell leukemia regimens, 531 cladribine and, 109 interferon-a 42 Halaven. See eribulin halofantrine haloperidol H2-blockers Index 649
650 Index HCC. See hepatocellular cancer (HCC) HDAC inhibitor. See histone deacetylase (HDAC) inhibitor head and neck cancer bleomycin and, 57 carboplatin and, 87 cetuximab and, 97 514 518 cisplatin and, 104, 105 docetaxel and, 154, 155 5-fluorouracil 05 hydroxyurea 22 ifosfamide 33 methotrexate 86 mitomycin-c 92 paclitaxel and, 323 hemangioma interferon-a 42 heparin dacarbazine and, 130 daunorubicin and, 139 epirubicin and, 171 idarubicin 29 mitoxantrone 99 hepatic function, and dosage, 450 456 hepatocellular cancer (HCC) regimens, 518 519 hepatoma 5-fluorouracil 05 Herceptin. See trastuzumab Herskovic regimen, 507 508 Hexalen. See altretamine Hexamethylmelamine. See altretamine histone deacetylase (HDAC) inhibitor romidepsin, 363 365 vorinostat, 441 443 HMM. See altretamine Hodgkin s lymphoma bleomycin and, 57 brentuximab and, 68 carmustine and, 94 540 543 chlorambucil and, 101 dacarbazine and, 130 etoposide and, 185 gemcitabine 17 ifosfamide 33 lomustine 71 mechlorethamine 74 primary induction procarbazine and, 353 thiotepa and, 396 Hopkins/Yale regimen, 508 hormonal agents abiraterone acetate, 5 7 albumin-bound paclitaxel, 11 13 aminoglutethimide, 23 25 anastrozole, 26 28 bicalutamide, 54 55 degarelix, 148 149 enzalutamide, 167 169 exemestane, 195 196 flutamide, 208 209 fulvestrant, 210 211 goserelin, 219 220 letrozole, 264 266 leuprolide, 267 269 megestrol acetate, 276 278 nilutamide, 308 310 tamoxifen, 378 381 toremifene, 401 403 H2-receptor inhibitors vismodegib and, 439 5-HT3 receptor antagonist dolasetron, 608 610 granisetron, 613 615 ondansetron, 624 626 palonosetron, 627 629 HuMax-CD20. See ofatumumab Hycamtin. See topotecan Hydrea. See hydroxyurea hydrocortisone dacarbazine and, 130 Hydroxydaunorubicin. See doxorubicin hydroxyurea, 221 223, 531 cytarabine and, 123 453, 459 Hyper-CVAD/MTX-Ara-C regimen, 551 552 Hyper-CVAD regimen, 523 hypereosinophilic syndrome (HES) imatinib 37, 238 hypomethylating agents azacitidine, 41 43 decitabine, 145 147 I ibritumomab, 224 227 ibritumomab tiuxetan regimen, 552 ibutilide IBW. See ideal body weight (IBW) ICE (salvage regimen), 548 549 Iclusig. See ponatinib Idamycin. See idarubicin idarubicin, 228 231 453, 459 ideal body weight (IBW), 449 450 IDEC-Y2B8. See ibritumomab Ifex. See ifosfamide IFL Saltz regimen, 496 497 IFN-a. See interferon-a IFN 1 DTIC regimen, 555 ifosfamide, 232 235 cisplatin and, 105 453, 459 IL-2. See aldesleukin imatinib, 236 240, 513 514, 524, 530, 563 453, 459
Imidazole Carboxamide. See dacarbazine immunomodulatory agent thalidomide, 388 391 immunomodulatory analog of thalidomide lenalidomide, 260 263 pomalidomide, 341 344 immunotherapy aldesleukin, 14 16 denileukin difitox, 150 152 interferon-a, 241 244 sipuleucel-t, 366 367 indinavir Inlyta. See axitinib interferon-a, 241 244, 520 453, 459 Interferon-a2a. See interferon- a interleukin-2 453, 459 Intron A. See interferon- a ionizing radiation cytarabine and, 123 IPB regimen, 512 ipilimumab, 245 248 IP regimen, 512 Iressa. See gefitinib irinotecan, 249 253, 475, 493 colorectal cancer and cetuximab, 97 453, 459 IROX regimen, 500 Isophosphamide. See ifosfamide isotretinoin 453, 459 Istodax. See romidepsin ITP regimen, 470 itraconazole bexarotene and, 52 busulfan and, 71 cabozantinib and, 78 dasatinib and, 136 everolimus and, 193 exemestane and, 196 gefitinib 13 imatinib 38 ironotecan 51 ixabepilone 55 lapatinib 58 letrozole 65 nilotinib and, 306 temsirolimus and, 386 IVAC regimen, 550 ixabepilone, 254 256, 487 454, 459 Ixempra. See ixabepilone J Jevtana. See cabazitaxel K Kadcyla. See ado-trastuzumab emtansine Kaposi s sarcoma regimens, 519 520 daunorubicin liposome and, 143 doxorubicin liposome and, 164 interferon-a 42 paclitaxel and, 323 Karnofsky performance scale, 448 ketoconazole bexarotene and, 52 bortezomib and, 61 cabozantinib and, 78 dasatinib and, 136 docetaxel and, 155 erlotinib and, 179 everolimus and, 193 exemestane and, 196 gefitinib 13 imatinib 38 ironotecan 51 ixabepilone 55 lapatinib 58 letrozole 65 nilotinib and, 306 temsirolimus and, 386 toremifene and, 402 tretinoin and, 415 Kyprolis. See carfilzomib Kytril and Sancuso Transdermal Patch. See granisetron L lansoprazole lapatinib, 257 259 dialysis guidelines, 463 454, 459 Larson regimen, 522 523 laryngeal cancer neoadjuvant L-Asparaginase. See asparaginase Index 651
652 Index lenalidomide, 260 263, 530, 553, 562 454, 459 leptomeningeal carcinomatosis cytarabine and, 123 letrozole, 264 266, 480, 486 adjuvant treatment to local treatment modalities, 3 leucovorin capecitabine and, 83 floxuridine and, 198 5-fluorouracil 06 methotrexate 87 pemetrexed and, 336 pralatrexate and, 350 leukemia acute lymphoblastic, 2, 34, 112 acute promyelocytic, 30, 31 B-CLL, 17 chronic lymphocytic ( See chronic lymphocytic leukemia (CLL)) chronic myelomonocytic, 42 hairy cell, 109 T-cell prolymphocytic, 18 Leukeran. See chlorambucil leuprolide, 267 269 454, 459 Leustatin. See cladribine levodopa procarbazine and, 353 LHRH agonist goserelin, 219 220 leuprolide, 267 269 lidocaine dacarbazine and, 130 Linker regimen, 521 522 lomustine, 270 272 454, 459 lorazepam, 616 618 L-PAM. See melphalan Lupron. See leuprolide LV 5 FU 2 1 mitomycin-c regimen, 501 LY231514. See pemetrexed lymphoma anaplastic large cell, 68 Burkitt s, 2 540 554 etoposide and, 185 Hodgkin s ( See Hodgkin s lymphoma) mantle cell, 61 non-hodgkin s (See non-hodgkin s lymphoma) peripheral T-cell, 350 primary CNS ( See CNS lymphoma, primary) T-cell lymphoblastic, 303 Lysodren. See mitotane M MACOP-B, 547 MAGIC Trial for esophageal cancer, 508 magnesium hydroxide, capecitabine and, 83 Magrath Protocol, 549 550 MAID regimen, 577 malignant melanoma. See melanoma, malignant mantle cell lymphoma bortezomib and, 61 lenalidomide 61 Marinol. See dronabinol Matulane. See procarbazine Mayo Clinic schedule, 495, 500 m-bacod, 547 548 MCV regimen, 472 MDS. See myelodysplastic syndromes (MDS) mechlorethamine, 273 275 454, 459 medulloblastoma, 94 Megace. See megestrol acetate megestrol acetate, 276 278 454, 459 Mekinist. See trametinib melanoma, malignant aldesleukin and, 15 regimens, 555 557 dacarbazine and, 130 interferon-a 42 ipilimumab 45 temozolomide and, 383 trametinib and, 409 melphalan, 279 281, 561 454, 459 meningeal leukemia methotrexate 86 meperidine procarbazine and, 353 6-mercaptopurine, 282 284 454, 459 doxorubicin and, 160 mesna cisplatin and, 105 mesoridazine mesothelioma, malignant regimens, 557 558 pemetrexed and, 335 methadone methotrexate, 285 290, 518, 554 asparaginase and, 34 cisplatin and, 105 cytarabine and, 123 454, 459 5-fluorouracil 06 vincristine and, 432
metoclopramide, 619 621, 632, 634, 635 mfolfox 7 regimen, 495, 498 MINE (salvage regimen), 549 Mini-BEAM regimen, 542 Mitomycin. See mitomycin-c mitomycin-c, 291 294 454, 459 460 doxorubicin and, 160 vinorelbine and, 435 mitotane, 295 297 454, 460 mitoxantrone, 298 301 454, 460 fludarabine 02 monoclonal antibody alemtuzumab, 17 19 bevacizumab, 47 50 brentuximab, 67 69 cetuximab, 96 99 ibritumomab, 224 227 ipilimumab, 245 248 ofatumumab, 311 314 panitumumab, 327 329 pertuzumab, 338 340 rituximab, 355 358 tositumomab, 404 407 trastuzumab, 411 413 ziv-aflibercept, 444 446 MOPP/ABVD hybrid regimen, 541 MOPP regimen, 540 541 motion sickness diphenhydramine and, 607 moxifloxacin 6-MP. See 6-mercaptopurine MPL regimen, 559 MP regimen, 558 MPT regimen, 559 MTX. See methotrexate multiple myeloma bortezomib and, 61 carfilzomib and, 91 carmustine and, 94 regimens, 558 562 doxorubicin liposome and, 164 interferon-a 42 lenalidomide 61 melphalan 80 pomalidomide and, 342 thalidomide and, 389 Mustargen. See mechlorethamine Mutamycin. See mitomycin-c MVAC regimen, 471 myelodysplastic syndromes (MDS) azacitidine and, 42 562 563 decitabine and, 146 idarubicin 29 imatinib 37, 238 lenalidomide 61 thalidomide and, 389 myeloproliferative disease (MPD) imatinib 37, 238 myelosuppressive drugs carboplatin and, 87 thiotepa and, 396 Myleran. See busulfan N nabilone, 622 623, 635 natural product arsenic trioxide, 29 32 Navelbine. See vinorelbine nefazodone nelarabine, 302 304, 524 454, 460 nelfinavir neoadjuvant, 2 nephrotoxic agents streptozocin and, 372 neuroblastoma dacarbazine and, 130 Nexavar. See sorafenib Nilandron. See nilutamide nilotinib, 305 307, 514, 524, 530 460 nilutamide, 220, 308 310 454, 460 Nitrogen mustard. See mechlorethamine N-Methylhydrazine. See procarbazine Nolvadex. See tamoxifen nonclassic alkylating agent altretamine, 20 22 procarbazine, 352 354 temozolomide, 382 384 non-hodgkin s lymphoma bendamustine and, 45 bleomycin and, 57 carmustine and, 94 543 553 chlorambucil and, 101 cisplatin and, 104 cladribine and, 109 Index 653
654 Index non-hodgkin s lymphoma Cont. cytarabine and, 123 etoposide and, 185 fludarabine 02 gemcitabine 17 ibritumomab 25 ifosfamide 33 interferon-a 42 lomustine 71 mechlorethamine 74 methotrexate 86 mitoxantrone 99 ofatumumab and, 312 primary induction procarbazine and, 353 rituximab and, 360 thiotepa and, 396 tositumomab and, 405 non-small cell lung cancer (NSCLC) adjuvant treatment to local treatment modalities, 3 albumin-bound paclitaxel for, 12 bevacizumab and, 48, 49 carboplatin and, 87 regimens, 532 538 cisplatin and, 104, 105 docetaxel and, 154, 155 erlotinib and, 178 etoposide and, 185 etoposide phosphate and, 189 gefitinib 13 gemcitabine and, 216, 217 ifosfamide 33 ironotecan 51 mitomycin-c 92 neoadjuvant paclitaxel and, 323 pemetrexed and, 335 vinorelbine and, 435 nonsteroidal antiinflammatory drugs (NSAIDs) pemetrexed and, 336 pralatrexate and, 350 nonsteroidal aromatase inhibitor anastrozole, 26 28 nontaxane eribulin, 174 176 Novantrone. See mitoxantrone NSAIDs. See nonsteroidal anti-inflammatory drugs (NSAIDs) O octreotide, 490 ofatumumab, 311 314, 529 454, 460 omacetaxine mepesuccinate, 315 317 Oncovin. See vincristine ondansetron, 624 626, 632, 633, 634 635 cisplatin and, 106 Ontak. See denileukin difitox OSI-774. See erlotinib osteogenic sarcoma adjuvant treatment to local treatment modalities, 3 563 564 ifosfamide 33 methotrexate 86 neoadjuvant ovarian cancer altretamine 1 carboplatin and, 87 564 568 cisplatin and, 104 and, 118 docetaxel and, 154 doxorubicin liposome and, 164 etoposide and, 185 5-fluorouracil 05 gemcitabine 16 hydroxyurea 22 melphalan 80 paclitaxel and, 323 thiotepa and, 396 topotecan and, 399 vinorelbine and, 435 oxaliplatin, 318 321 capecitabine and, 83 454, 460 oxygen, bleomycin and, 57 P paclitaxel, 322 326, 473, 487, 493, 507, 510, 517 518, 520 albumin-bound, 11 13 carboplatin and, 88 cisplatin and, 105 dialysis guidelines, 463 455, 460 vincristine and, 432 palonosetron, 627 629, 633, 634 pancreatic cancer 568 571 erlotinib and, 178 5-fluorouracil 05 gemcitabine 16, 217 mitomycin-c 92 oxaliplatin and, 319 streptozocin and, 372 pancreatic neuroendocrine tumors (PNET) panitumumab, 327 329, 505 455, 460 Paraplatin. See carboplatin Parkinsonism diphenhydramine and, 607
paroxetine pazopanib, 330 333 455, 460 PCB regimen, 534 PCE regimen, 488 PCR regimen, 527 PCV regimen, 473, 474 PD regimen, 560 PEB regimen, 57, 488, 578 579 pegasparaginase 455, 460 Peginterferon-a2b. See interferon- a pemetrexed, 334 337, 473, 493 455, 460 penicillins methotrexate 87 pralatrexate and, 350 pentamidine pentostatin, 530 performance scales, 448 peripheral T-cell lymphoma (PTCL) pralatrexate and, 350 Perjeta. See pertuzumab perphenazine pertuzumab, 338 340 455, 460 PF 1 cetuximab regimen, 516 PF-larynx preservation, 517 PF regimen, 516 P-glycoprotein (Pgp) inhibitors nilotinib and, 306 vismodegib and, 439 phenobarbital bexarotene and, 52 busulfan and, 71 cabozantinib and, 78 chlorambucil and, 101 dacarbazine and, 130 dasatinib and, 136 doxorubicin and, 160 erlotinib and, 178 everolimus and, 192 exemestane and, 196 gefitinib 13 ifosfamide 33 imatinib 38 interferon-a 42 ironotecan 51 ixabepilone 55 lapatinib 58 letrozole 65 nilotinib and, 306 paclitaxel and, 324 temsirolimus and, 386 toremifene and, 402 tretinoin and, 415 phenothiazine prochlorperazine, 630 631 Phenylalanine mustard. See melphalan phenytoin bexarotene and, 52 busulfan and, 71 cabozantinib and, 78 capecitabine and, 83 carmustine and, 94 chlorambucil and, 101 cisplatin and, 105 dacarbazine and, 130 doxorubicin and, 160 ifosfamide 33 interferon-a 42 methotrexate 87 mitotane 96 paclitaxel and, 324 streptozocin and, 372 temsirolimus and, 386 toremifene and, 402 vinorelbine and, 435 pimozide Platinol. See cisplatin platinum analogs carboplatin, 86 89 cisplatin, 103 107 oxaliplatin, 318 321 platinum-based erlotinib and, 179 PLX4032. See vemurafenib PNET. See pancreatic neuroendocrine tumors (PNET) polycythemia vera hydroxyurea 22 melphalan 80 pomalidomide, 341 344 455, 460 Pomalyst. See pomalidomide ponatinib, 345 348, 531 455, 460 PONV. See postoperative nausea and vomiting (PONV) posaconazole Index 655
656 Index postoperative nausea and vomiting (PONV) aprepitant and, 603 dolasetron and, 609 granisetron and, 614 pralatrexate, 349 351, 552 553 455, 460 prednisone, 529 pregnancy, use of agents in, 464 465 primary induction, 2 probenecid idarubicin 29 methotrexate 87 pralatrexate and, 350 procainamide procarbazine, 352 354, 475 455, 460 prochlorperazine, 630 631, 632, 635 progestational agents megestrol acetate, 276 278 Proleukin. See aldesleukin ProMACE/CytaBOM regimen, 548 prostate cancer abiraterone acetate for, 6 aminoglutethimide 3 bicalutamide and, 55 571 575 degarelix and, 149 docetaxel and, 154, 155 enzalutamide and, 168 estramustine and, 182 flutamide 09 goserelin 19 leuprolide 67 mitoxantrone 99 nilutamide and, 309 paclitaxel and, 323 sipuleucel-t and, 367 proteasome inhibitor bortezomib, 60 63 carfilzomib, 90 92 protein synthesis inhibitor omacetaxine mepesuccinate, 315 317 proton pump inhibitors methotrexate 87 vismodegib and, 439 Provenge. See sipuleucel-t PTCL. See peripheral T-cell lymphoma (PTCL) Purinethol. See 6-mercaptopurine PVB regimen, 579 Q quinidine R RAD001. See everolimus radiation therapy bleomycin and, 58 cisplatin and, 105 docetaxel and, 155 gemcitabine 17 paclitaxel and, 323 R-CHOP regimen, 544 545 R-CHOP- 14 regimen, 546 refractory anemia azacitidine and, 42 Reglan. See metoclopramide regorafenib, 355 358, 505 455, 461 renal cell cancer aldesleukin and, 15 bevacizumab and, 48 575 576 interferon-a 42 megestrol acetate 77 temsirolimus and, 386 reserpine thalidomide and, 389 retinoid bexarotene, 51 53 tretinoin, 414 417 retinoid X receptor (RXR), 51 Revlimid. See lenalidomide R-FCM regimen, 545 R-GemOx (salvage regimen), 549 rhabdomyosarcoma dactinomycin-d, 133 embryonal, 2 RICE (salvage regimen), 549 rifampicin ixabepilone 55 lapatinib 58 letrozole 65 rifampin bexarotene and, 52 cabozantinib and, 78 dasatinib and, 136 erlotinib and, 178 everolimus and, 192 exemestane and, 196 gefitinib 13 imatinib 38 ironotecan 51 nilotinib and, 306 temsirolimus and, 386 tretinoin and, 415 ritonavir
Rituxan. See rituximab rituximab, 355 358, 529, 552 and B-cell non-hodgkin s lymphoma, 45 455, 461 ibritumomab 25 RMPT regimen, 561 Roferon Interferon-a2b. See interferon-a romidepsin, 363 365, 553 Roswell Park schedule, high dose regimen, 500 RTOG chemoradiation regimen, 568 569 RTOG/ECOG regimen, 467 Rubidomycin. See daunorubicin RVD regimen, 560 S salvage, 468 saquinavir sertraline SGN-35. See brentuximab signal transduction inhibitor axitinib, 37 40 bosutinib, 64 66 cabozantinib, 77 79 crizotinib, 114 116 dabrafenib, 126 128 dasatinib, 135 137 erlotinib, 177 180 everolimus, 191 194 gefitinib, 212 214 imatinib, 236 240 lapatinib, 257 259 nilotinib, 305 307 pazopanib, 330 333 ponatinib, 345 348 regorafenib, 355 358 sorafenib, 368 370 sunitinib, 374 377 temsirolimus, 385 387 trametinib, 408 410 vandetanib, 418 421 vemurafenib, 422 425 vismodegib, 438 440 sipuleucel-t, 366 367 6-Thioguanine. See thioguanine SKI-606. See bosutinib skin cancer. See also cutaneous T-cell lymphoma (CTCL); melanoma, malignant bleomycin and, 57 5-fluorouracil 05 small cell lung cancer carboplatin and, 87 538 540 cisplatin and, 104 docetaxel and, 154 etoposide and, 185 etoposide phosphate and, 189 ifosfamide 33 ironotecan 51 paclitaxel and, 323 topotecan and, 399 sodium thiosulfate mechlorethamine 74 soft tissue sarcoma (STS) 576 578 dacarbazine and, 130 gemcitabine 17 ifosfamide 33 sorafenib, 368 370, 514, 519 455, 461 sotalol sparfloxacin Sprycel. See dasatinib squamous cell carcinomas bleomycin and, 57 St. John s Wort bortezomib and, 62 cabozantinib and, 78 dasatinib and, 136 erlotinib and, 178 179 everolimus and, 192 exemestane and, 196 gefitinib 13 imatinib 38 ironotecan 51 ixabepilone 55 lapatinib 58 letrozole 65 nilotinib and, 306 temsirolimus and, 386 Stanford regimen, 550 551 Stanford V regimen, 541 stem cell transplant busulfan with in, 71 carboplatin dose during, 87 steroidal aromatase inactivator exemestane, 195 196 Index 657
658 Index steroids melphalan 80 mitotane 96 streptozocin and, 372 STI571. See imatinib Stivarga. See regorafenib streptozocin, 371 373 455, 461 Streptozotocin. See streptozocin STS. See soft tissue sarcoma (STS) SU11248. See sunitinib substance P/NK1 receptor antagonist aprepitant, 602 603 substituted benzamide metoclopramide, 619 621 sulfamethoxazole pralatrexate and, 350 sulfinpyrazone idarubicin 29 sunitinib, 374 377, 490, 514 455, 461 Sutent. See sunitinib Synribo. See omacetaxine mepesuccinate T TAC regimen, 476 477 Tafinlar. See dabrafenib T-ALL. See T-cell acute lymphoblastic leukemia (T-ALL) tamoxifen, 378 381, 480, 486 adjuvant treatment to local treatment modalities, 3 455, 461 Tarceva. See erlotinib Targretin. See bexarotene Tasigna. See nilotinib taxanes albumin-bound paclitaxel, 11 13 cabazitaxel, 73 76 docetaxel, 153 157 paclitaxel, 322 326 trastuzumab and, 412 Taxol. See paclitaxel Taxotere. See docetaxel T-cell acute lymphoblastic leukemia (T-ALL) nelarabine and, 303 T-cell lymphoblastic lymphoma (T-LBL) nelarabine and, 303 T-cell prolymphocytic leukemia alemtuzumab and, 18 TCH regimen, 479, 484 TC regimen, 476 telithromycin Temodar. See temozolomide temozolomide, 382 384, 475, 554 dialysis guidelines, 464 455, 461 temsirolimus, 385 387 dialysis guidelines, 464 461 teratogenic potential, agents, 464 465 terfenadine testicular cancer bleomycin and, 57 578 580 cisplatin and, 104, 105 etoposide and, 185 etoposide phosphate and, 189 ifosfamide 33 thalidomide, 388 391, 561 455, 461 Thalomid. See thalidomide thiazide diuretics toremifene and, 402 thiethylperazine, 632 thioguanine, 392 394 456, 461 Thioplex. See thiotepa thioridazine thiotepa, 395 397 456, 461 thrombocytosis hydroxyurea 22 thymidine floxuridine and, 198 5-fluorouracil 06 methotrexate 87 pemetrexed and, 336 pralatrexate and, 350 thymoma regimens, 580 581 thyroid cancer cabozantinib and, 78 regimens, 581 582 ticlopidine TIC regimen, 515 TIP (salvage regimen), 580 TIP regimen, 515 T-LBL. See T-cell lymphoblastic lymphoma (T-LBL) topoisomerase II inhibitor etoposide, 184 187 etoposide phosphate, 188 190
topoisomerase I inhibitor ironotecan, 249 253 topotecan, 398 400 topotecan, 398 400, 493, 507, 554 456, 461 toremifene, 401 403, 486 Torisel. See temsirolimus tositumomab, 404 407 TPF induction followed by carboplatin 1 radiation therapy, 514 515 TPF regimen, 515 trametinib, 408 410 456, 461 trastuzumab, 411 413, 486 456, 461 doxorubicin and, 160 pertuzumab and, 339 Treanda. See bendamustine tretinoin, 414 417 456, 461 tricyclic antidepressants procarbazine and, 353 Triethylenethiophosphoramide. See thiotepa trimethroprim pralatrexate and, 350 trimetrexate 5-fluorouracil 06 Trisenox. See arsenic trioxide (As 2 O 3 ) troleandomycin trophoblastic neoplasms cisplatin and, 104 Tykerb. See lapatinib U unclassified therapeutic agent lenalidomide, 260 263 pomalidomide, 341 344 thalidomide, 388 391 V VAB-6 regimen, 579 VAD regimen, 559 vandetanib, 418 421 VCR. See vincristine Vectibix. See panitumumab VeIP (salvage regimen), 579 580 Velban. See vinblastine Velcade. See bortezomib vemurafenib, 422 425 456 VePesid. See etoposide verapamil everolimus and, 193 ixabepilone 55 tretinoin and, 415 vermurafenib dialysis guidelines, 464 Vesanoid. See tretinoin Vidaza. See azacitidine vinblastine, 426 429 dialysis guidelines, 464 456, 461 vinca alkaloid vinblastine, 426 429 vincristine, 430 433 vinorelbine, 434 437 vincristine, 430 433 asparaginase and, 34 456, 461 vinorelbine, 434 437, 487, 518, 520 456, 461 VIP (salvage regimen), 580 VIP regimen, 581 vismodegib, 438 440 vismodegih, 469 vistonuridine (PN401 ) floxuridine and, 198 5-fluorouracil 06 vitamin A supplements tretinoin and, 415 voriconazole vorinostat, 441 443 456, 461 Votrient. See pazopanib VP-16. See etoposide VP regimen, 517 W Waldenstrom s macroglobulinemia chlorambucil and, 101 warfarin bicalutamide and, 55 capecitabine and, 83 erlotinib and, 179 etoposide and, 185 etoposide phosphate and, 189 flutamide 09 gefitinib 13 ifosfamide 34 imatinib and, 238 239 lapatinib 58 letrozole 65 methotrexate and, 287 mitotane 96 nilutamide and, 309 tamoxifen and, 379 toremifene and, 402 vemurafenib and, 423 vorinostat and, 442 Index 659
Wilms tumor adjuvant treatment to local treatment modalities, 3 dactinomycin-d, 133 primary induction X Xalkori. See crizotinib XELIRI regimen, 499 500 Xeloda. See capecitabine XELOX 1 bevacizumab regimen, 501 XELOX 1 radiation therapy, 468, 494 495 XELOX regimen, 82, 496, 499 XP 1 trastuzumab regimen, 512 Xtandi. See enzalutamide Y Yervoy. See ipilimumab Z Zaltrap. S ee ziv-aflibercept Zanosar. See streptozocin ZD1839. See gefitinib Zelboraf. See vemurafenib Zevalin. See ibritumomab ziv-aflibercept, 444 446 Zofran. See ondansetron Zoladex. See goserelin Zolinza. See vorinostat Zytiga. See abiraterone acetate 660 Index
Index 661
662 Index
Index 663
664 Index